Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

7 treatments under study, led by Diclofenac

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

16.7%

1 terminated out of 6 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (1)
Phase 1 (2)
Phase 3 (2)
Phase 4 (1)

Trial Status

Unknown2
Withdrawn2
Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00567372Phase 4WithdrawnPrimary

POSTERIOR SUB-TENON'S Avastin

NCT00571142Phase 3TerminatedPrimary

Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

NCT00600301Phase 3WithdrawnPrimary

Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

NCT00886808Phase 1CompletedPrimary

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

NCT01218750Not ApplicableUnknownPrimary

Triple Therapy for Diffuse Diabetic Macular Edema

NCT00999791Phase 1UnknownPrimary

Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema

Showing all 6 trials

Research Network

Common Treatments

  • Diclofenac1
  • Triple Therapy For Diffuse Diabetic Macular Edema1
  • Bevacizumab Pars Plana Vitrectomy1
  • Ico007 Intravitreal Injection1
  • Bevacizumab1

Active Sponsors

  • Asociación para Evitar la Ceguera en México3
  • Military Institute od Medicine National Research Institute1
  • iCo Therapeutics Inc.1
  • Shahid Beheshti University of Medical Sciences1

Top Investigators

Activity Timeline